Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine.

@article{Belshe2004SafetyIA,
  title={Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine.},
  author={Robert B. Belshe and Min-Shi Lee and Robert E. Walker and Jeffrey Stoddard and Paul M. Mendelman},
  journal={Expert review of vaccines},
  year={2004},
  volume={3 6},
  pages={643-54}
}
Data supporting the use of the live attenuated influenza vaccine (LAIV) in children and adults is reviewed, and the development and characteristics of the vaccine are summarized. The vaccine is highly effective and well tolerated in children and adults from 5 to 49 years of age. Correlates of immune protection include serum hemagglutination-inhibition… CONTINUE READING